ArticleBMC infectious diseases2026
Optimizing COVID-19 vaccination for older adults: superior efficacy of heterologous regimens in reducing infection and mortality rates among patients aged 80 years and older during the Omicron BA.5/BF.7 outbreak.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFollowing the adjustment of COVID-19 control policies in mainland China, particularly during the Omicron BA.5 and BF.7 waves, evaluating vaccine effectiveness in individuals aged ≥ 80 years is of critical importance. PATIENTS AND
methodsThis retrospective study included 2,325 hospitalized patients aged 80 years and older from four hospitals between December 9, 2022, and January 27, 2023. We assessed the associations of vaccination dose, vaccination regimen, and the interval since the last vaccination with SARS-CoV-2 infection and mortality. Univariable and multivariable logistic regression analyses were performed to adjust for baseline imbalances across vaccination groups. An exploratory NAb analysis was conducted in 138 patients with paired serum samples at admission and discharge to evaluate immune responses associated with different vaccination strategies.
resultsIn the unadjusted analyses, SARS-CoV-2 infection and mortality rates decreased with increasing vaccine doses. After adjustment for age, diabetes, and hyperlipidemia, receipt of 1, 2, and 3 vaccine doses was associated with lower odds of SARS-CoV-2 infection compared with no vaccination, with adjusted ORs of 0.644 (95% CI: 0.445-0.931, P = 0.019), 0.579 (95% CI: 0.407-0.823, P = 0.002), and 0.448 (95% CI: 0.332-0.607, P < 0.001), respectively. Three-dose vaccination was also associated with lower odds of mortality (OR = 0.563, 95% CI: 0.380-0.835, P = 0.004). In the regimen-based model, CoronaVac plus ZF2001 was associated with lower odds of infection (OR = 0.456, 95% CI: 0.235-0.885, P = 0.020) and mortality (OR = 0.410, 95% CI: 0.123-0.878, P = 0.047) after adjustment. In the exploratory NAb subgroup analysis, patients receiving CoronaVac plus ZF2001 showed higher NAb levels at both admission and discharge.
conclusionsDuring the Omicron BA.5/BF.7 wave, receipt of three COVID-19 vaccine doses was associated with lower risks of SARS-CoV-2 infection and mortality among hospitalized patients aged 80 years and older. The heterologous regimen of CoronaVac plus ZF2001 was associated with lower risks of infection and mortality and higher NAb levels. These findings support the potential value of optimized booster and heterologous vaccination strategies for improving COVID-19-related outcomes in this high-risk older population. CLINICAL TRIAL: N/A.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.